Cn /En

News Center

——

Company news

Industry news

InnoModels Biotechnology 3D Organoid Platform: Key Functions Explained

Author:

InnoModels

Release time:

2024-07-12

In the vast ocean of drug discovery and development, scientists are always looking for a tool that can more accurately predict the efficacy of drugs, reduce the cost of research and development, and increase the success rate. The 3D organoid platform is such a cutting-edge biological research tool, which plays a crucial role in the field of new drug development with its unique advantages.
Introduction of the 3D Organoid Platform:
The 3D organoid platform is based on the innovative technology of the InnoModels Biotechnology Clinical Tumor Biospecimen Library, which shares the same set of models with the PDC (In Vitro Drug Detection Platform) and PDX (Patient-Derived Xenograft Models) platforms, providing a seamless connection to the entire process of new drug discovery and development. From in vitro high-throughput screening to in vivo studies, this platform maintains the continuity of the model, ensuring the consistency and reliability of experimental data.
Key Features Explained:
1. Rapid prediction of drug efficacy
The 3D organoid platform can rapidly predict the effectiveness of drugs in the clinic and provide early feedback to researchers. By constructing 3D organoid models that are highly similar to human tissues, the platform can simulate the drug efficacy response in the human body, providing an important basis for new drug development.
2. Drug screening and optimization
The platform is able to screen out test drugs with higher development potential from alternative compounds and optimize the allocation of resources. In the early stage of drug development, the platform can help researchers quickly screen potential drug candidates, laying the foundation for subsequent in vivo studies.
3. Model Screening and Selection
Based on the response of the drug to the model, the 3D organoid platform can select the most adaptable model for subsequent in vivo experiments. This model screening function helps to ensure the accuracy and reliability of experimental data and improve the success rate of new drug development.

4. Comparison of drug efficacy and difference analysis
By comparing with counterpart drugs or clinical therapeutic drugs, the platform can visualize the differences in efficacy and effective models. This comparative analysis helps researchers to more accurately assess the efficacy and safety of drugs, providing strong support for drug marketing.
5. Disease specificity analysis
The platform can compare efficacy differences between different cancer model cohorts to determine the best indication for a drug. This disease-specific analysis helps provide targeted strategies for drug development to meet the needs of patients with different disease types.
6. Efficacy and resistance analysis
Based on efficacy data, the InnoModels Biotechnology 3D organoid platform can differentiate models into effective and resistant models. Further, based on the differences in genetic characteristics between models and before and after treatment, the platform can deeply explore the mechanism of drug action, providing powerful support for drug optimization and personalized treatment.
7. Biomarker discovery
By categorizing models according to their efficacy and analyzing the differences in genetic profiles of different groups based on histology, the platform aims to find biomarkers that can predict the efficacy of drugs. These biomarkers are expected to become an important tool for new drug development, helping doctors to more accurately predict patients' treatment effects.
Summary:
With its unique technical advantages and key functions, the 3D organoid platform of InnoModels Biotechnology plays an important role in the field of new drug development. The platform is capable of rapidly predicting drug efficacy, optimizing drug screening and configuration, selecting the most adapted models for in vivo studies, intuitively comparing differences in drug efficacy and disease-specific analysis, and discovering biomarkers. In the future, with the continuous advancement of technology and the expansion of applications, the 3D organoid platform of InnoModels will play an even more important role in the field of new drug research and development, and make greater contributions to the cause of human health.

Introducing the InnoModels Biotechnology In-Situ Modeling Platform

InnoModels Biotechnology bioidentical models: what are the main features

Introducing the InnoModels Biotechnology In-Situ Modeling Platform

InnoModels Biotechnology bioidentical models: what are the main features

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License